Tvardi Therapeutics (TVRD)

• Market cap: $62.7M
• 1 day: -83.92%
• 5 days: -82.92%
• 1 month: -80.18%
• 3 months: -77.57%
• 6 months: -59.82%
• Year to date: -58.4%
• 1 year: -27.44%
• 5 years: -98.65%
• 10 years: -98.63%
• Sector: Healthcare
• Industry: Biotechnology

About: Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.